AAP
KALV

Arax Advisory Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Arax Advisory Partners’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$4.04K – 4086
2025
Q4 		$4.04K Sell
250
-721
-74% -$9.55K ﹤0.01% 2962
2025
Q3 		$11.8K Buy
+971
New +$13.4K ﹤0.01% 2519

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Arax Advisory Partners's KALV Position: Q1 2026 in Review

Arax Advisory Partners sold out of KalVista Pharmaceuticals (KALV) in Q1 2026, closing a stake of 250 shares — an estimated $4.04K sold.

Arax Advisory Partners first reported a position in KALV in Q3 2025 and held it in 2 quarters. The position peaked at $11.8K in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Arax Advisory Partners reported no remaining KalVista Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 250 KalVista Pharmaceuticals shares in Q1 2026, an estimated $4.04K.
  • Arax Advisory Partners first reported a position in KalVista Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's KalVista Pharmaceuticals position peaked at $11.8K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.